Weekly Research Analysts’ Ratings Changes for Cidara Therapeutics (CDTX)

Several brokerages have updated their recommendations and price targets on shares of Cidara Therapeutics (NASDAQ: CDTX) in the last few weeks:

• 11/18/2025 – Cidara Therapeutics had its “neutral” rating reaffirmed by analysts at Guggenheim.
• 11/17/2025 – Cidara Therapeutics was downgraded by analysts at Royal Bank Of Canada from an “outperform” rating to a “sector perform” rating.
• 11/17/2025 – Cidara Therapeutics was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating.
• 11/17/2025 – Cidara Therapeutics was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating.
• 11/14/2025 – Cidara Therapeutics was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating.
• 11/14/2025 – Cidara Therapeutics was downgraded by analysts at Needham & Company LLC from a “buy” rating to a “hold” rating.
• 11/8/2025 – Cidara Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/7/2025 – Cidara Therapeutics had its price target raised by analysts at Royal Bank Of Canada from $137.00 to $145.00. They now have an “outperform” rating on the stock.
• 11/7/2025 – Cidara Therapeutics had its price target raised by analysts at Needham & Company LLC from $100.00 to $135.00. They now have a “buy” rating on the stock.
• 10/21/2025 – Cidara Therapeutics had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 10/21/2025 – Cidara Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $150.00 price target on the stock.
• 10/16/2025 – Cidara Therapeutics is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $190.00 price target on the stock.
• 10/10/2025 – Cidara Therapeutics is now covered by analysts at JPMorgan Chase & Co.. They set an “overweight” rating and a $200.00 price target on the stock.
• 10/9/2025 – Cidara Therapeutics had its price target raised by analysts at WBB Securities from $123.00 to $199.00. They now have a “strong-buy” rating on the stock.
• 10/9/2025 – Cidara Therapeutics had its price target raised by analysts at HC Wainwright from $110.00 to $150.00. They now have a “buy” rating on the stock.
• 10/8/2025 – Cidara Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/3/2025 – Cidara Therapeutics was given a new $173.00 price target on by analysts at JMP Securities. They now have a “market outperform” rating on the stock.
• 9/27/2025 – Cidara Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/26/2025 – Cidara Therapeutics had its price target raised by analysts at HC Wainwright from $74.00 to $110.00. They now have a “buy” rating on the stock.
• 9/24/2025 – Cidara Therapeutics had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 9/24/2025 – Cidara Therapeutics was given a new $153.00 price target on by analysts at JMP Securities.
• 9/24/2025 – Cidara Therapeutics was given a new $167.00 price target on by analysts at Guggenheim. They now have a “buy” rating on the stock.
• 9/24/2025 – Cidara Therapeutics was given a new $137.00 price target on by analysts at Royal Bank Of Canada. They now have an “outperform” rating on the stock.
• 9/24/2025 – Cidara Therapeutics had its price target raised by analysts at Needham & Company LLC from $74.00 to $100.00. They now have a “buy” rating on the stock.
• 9/22/2025 – Cidara Therapeutics had its “strong-buy” rating reaffirmed by analysts at WBB Securities. They now have a $123.00 price target on the stock.
• 9/22/2025 – Cidara Therapeutics had its price target raised by analysts at WBB Securities from $45.00 to $123.00. They now have a “strong-buy” rating on the stock.

Insider Buying and Selling at Cidara Therapeutics

In related news, insider Nicole Negar Davarpanah sold 474 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $62.86, for a total transaction of $29,795.64. Following the sale, the insider owned 31,418 shares of the company’s stock, valued at $1,974,935.48. The trade was a 1.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.89% of the company’s stock.

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.